Document is current
Any future updates will be listed below
-
Authors
Kondoh, Yasuhiro https://orcid.org/0000-0001-7456-5459
Inoue, Yoshikazu
-
Funding
Funding for this research was provided by:
Nippon Boehringer Ingelheim Co., Ltd.
- License Information
-
More Information
Article History
Received: 29 January 2025
Accepted: 17 April 2025
First Online: 19 May 2025
Declarations
:
: The authors did not receive payment for development of this manuscript. Yasuhiro Kondoh reports advisory board fees from Asahi Kasei Pharma Corp, Boehringer Ingelheim, Chugai Pharmaceutical Co., Ltd., GSK, Healios K.K., Janssen Pharmaceutical K.K., Mochida Pharmaceutical Co., LTD, Sanofi K.K., Shionogi Co, Ltd., Taiho Pharmaceutical Co., and lecture fees from Asahi Kasei Pharma Corp, Bristol Myers Squibb, Boehringer Ingelheim, Eisai Co, Ltd, Janssen Pharmaceutical K.K., KYORIN Pharmaceutical Co, Ltd, Mitsubishi Tanabe Pharma, NIPPON SHINYAKU CO., LTD, Novartis Pharma K.K., Shionogi Co, Ltd., Teijin Pharma Ltd. Yoshikazu Inoue reports grants from the Japanese Ministry of Health, Labour, and Welfare and the Japan Agency for Medical Research and Development; payment for presentations from Boehringer Ingelheim, Kyorin, Shionogi, GlaxoSmithKline, ThermoFisher; and has served as a consultant or steering committee member for Boehringer Ingelheim, Galapagos, Roche, Taiho, CSL Behring, Vicore Pharma, Savara.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.
